Chance Pharmaceuticals Completes Series C+ Funding to Advance Innovative Pipeline and Business Collaborations
January 04, 2022 04:00 ET
|
Hangzhou Chance Pharma
HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals ("Chance"), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation...
Chance Pharmaceuticals Secures $30 Million Series C Funding to Advance Innovative Pipeline and Initiate Additional Business Collaborations
October 10, 2021 20:00 ET
|
Hangzhou Chance Pharma
HANGZHOU, China, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation...
Hangzhou Chance Pharmaceuticals Appoints Guobao Zhao as Senior Vice President
September 29, 2021 20:59 ET
|
Hangzhou Chance Pharma
HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing...
Hangzhou Chance Pharmaceuticals Announces NMPA Acceptance of Marketing Authorization Application for CXF11
July 01, 2021 20:49 ET
|
Hangzhou Chance Pharma
HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing...
杭州畅溪制药成功引⼊Aerami Therapeutics重磅品种AER-901
February 09, 2021 09:05 ET
|
Hangzhou Chance Pharma
中国杭州, Feb. 09, 2021 (GLOBE NEWSWIRE) -- 杭州畅溪制药（以下简称“畅溪”）与Aerami Therapeutics（以下简称“Aerami”）有限公司联合宣布其共同签署了⼀项独家许可及产品开发协议，畅溪将从Aerami获得其肺动脉高压候选药物AER-901在大中华地区（中国境内及港澳台）独家开发和商业化权利。 ...
Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics
February 09, 2021 09:05 ET
|
Hangzhou Chance Pharma
HANGZHOU, China, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing and commercializing...